1354223-67-8

Basic information

• Product Name: tert-butyl 2-chloro-5-fluoropyridin-4-ylcarbaMate
• Synonyms: tert-butyl 2-chloro-5-fluoropyridin-4-ylcarbaMate;4-N-Boc-aMino-2-chloro-5-fluoropyridine
• CAS NO: 1354223-67-8
• Molecular Formula: C10H12ClFN2O2
• Molecular Weight: 246.6658832
• Mol File: 1354223-67-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: tert-butyl 2-chloro-5-fluoropyridin-4-ylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-chloro-5-fluoropyridin-4-ylcarbaMate(1354223-67-8)
• EPA Substance Registry System: tert-butyl 2-chloro-5-fluoropyridin-4-ylcarbaMate(1354223-67-8)

Safety Data

• Hazardous Substances Data: 1354223-67-8(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 89510-90-7 4-amino-2-chloro-5-fluoropyridine 
• 884494-49-9 2-chloro-5-fluoro-4-iodopyridine 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 89510-90-7 4-amino-2-chloro-5-fluoropyridine 

Relevant articles and documents

ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS

The invention is directed to substituted isoquinoline derivatives and uses thereof. Specifically, the invention is directed to compounds according to Formula I and the use of compounds of Formula (I) in treating disease states: (I) wherein R1,

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

TGF BETA RECEPTOR ANTAGONISTS

The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβ R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.